Keros Therapeutics Stock News

Keros Therapeutics Inc (KROS) shares closed this week 21.0% higher than it did at the end of last week. The stock is currently down 10.2% year-to-date, down 22.3% over the past 12 months, and up 161.7% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $55.79 and as low as $42.32 this week.Trading volume this week was 0.7% higher than the 10-day average and 15.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -3.3% The company's stock price performance over the past 12 months beats the peer average by -34.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 9:20 am ET.

LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

Keros Therapeutics (KROS) has appointed Christopher Rovaldi as Keros'' Chief Operating Officer, effective as of February 1, 2022.Mr

Related Stocks: KROS , CRNX , OPTN , SMLR , FOLD , MRUS , DTIL , AADI , NCNA , MGNX , SIOX , APTO , AVEO , EPIX , MCRB , CMLF , LUMO , KZR , CRDF ,

Keros Therapeutics, Inc. (NASDAQ:KROS) insider Jennifer Lachey sold 735 shares of the firms stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $50.00, for a total transaction of $36,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this []

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) gapped down before the market opened on Tuesday . The stock had previously closed at $53.82, but opened at $47.00. Keros Therapeutics shares last traded at $47.02, with a volume of 303 shares trading hands. Separately, Zacks Investment Research upgraded Keros Therapeutics from a “sell” rating to a “hold” […]

Lexington, Mass. – December 13, 2021 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors under the heading "A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes," which incorrectly stated that none of the most commonly reported treatment-emergent adverse events observed as of the October 25, 2021 data cut-off date in the Phase 2 clinical trial of KER-050 were deemed to be related to study drug. However, one incidence each of nausea and diarrhea were attributed as related to study drug. All other data and disclosure remain unchanged.

LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS), as well as preclinical data on the differentiated mechanism of action of KER-050 and its activity in cytopenia models, at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in person and virtually December 11 through 14, 2021. In addition, Keros announced preclinical data evaluating ALK2 inhibition as a potential treatment option for anemia of inflammation.

Keros Therapeutics, Inc. (NASDAQ:KROS) Stock analysts at Piper Sandler cut their Q4 2021 earnings per share estimates for Keros Therapeutics in a research report issued to clients and investors on Tuesday, December 7th. Piper Sandler analyst J. Catanzaro now anticipates that the company will earn ($0.87) per share for the quarter, down from their []

Keros Therapeutics, Inc. (NASDAQ:KROS) Research analysts at Piper Sandler decreased their Q4 2021 earnings estimates for shares of Keros Therapeutics in a research note issued on Tuesday, December 7th. Piper Sandler analyst J. Catanzaro now forecasts that the company will post earnings per share of ($0.87) for the quarter, down from their prior forecast []

Keros Therapeutics, Inc. (NASDAQ:KROS)s stock price gapped down prior to trading on Monday . The stock had previously closed at $54.16, but opened at $51.32. Keros Therapeutics shares last traded at $53.84, with a volume of 5,370 shares traded. KROS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a buy []

Zacks Investment Research upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The companys []

Zacks Investment Research upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal []